Crinetics Pharmaceuticals

Our mission is to build the leading endocrine company that consistently pioneers new therapeutics to help patients better control their disease and improve their daily lives. Working to accomplish this mission is how we bring our vision to life. For us, that vision is the best possible therapeutics available to all patients with diseases of the endocrine system. We love how that sounds. And we really can’t wait to know how it feels. Notice of Fraudulent Activity for Job Applicants: Please be aware of fraudulent communications from job posting sites or email. Bad actors may try to impersonate Crinetics’ Talent Acquisition team, and their messages may appear legitimate. We strongly recommend you verify all communications you receive about positions at Crinetics. If you are unsure about a posting or email you receive, please contact us at [email protected].

dante genomics

Dante Genomics is a leading global genomics and precision medicine company working to deliver better healthcare and save lives with a more human approach to health. We work with customers across 97 countries and we create customized genomic analysis processes that have an impact on people’s lives. Our mission is to accelerate science for the people. We leverage genome sequencing technology and interpretation so that everyone can make informed decisions about their health and their future. We use the proprietary genomic platform, based on artificial intelligence and machine learning, capable of integrating and optimizing all resources and information, creating important synergies for our stakeholders. We also collaborate with international associations and advocacy groups to find solutions to improve the quality of life of patients. In 2019 the two founders won the EY award as "best entrepreneurs of the year" and the company took sixth place in the list of 2023 growth leaders compiled by Statista and Il Sole 24 Ore. More information is available at www.dantegenomics.com

Advanced Instruments, LLC

Our focus on service, quality, and reliability has made Advanced Instruments a leading developer and manufacturer of analytical instruments and services for the biopharmaceutical, clinical, and food & beverage industries for more than 65 years. Globally, we provide innovative technologies aligned with the needs of the markets we serve, helping to improve efficiency, enhance productivity, and ensure best-in-class performance. Our Solentim portfolio of best-in-class imaging and single-cell deposition technologies enables the clonal isolation, outgrowth, and characterization of the highest value cells for monoclonal antibody upstream development and cell and gene therapy. Our robust line of micro-osmometers is built specifically for the biotech industry and seamlessly integrate into both non-regulated and regulated GMP workflows ensuring increased yield, quality, and purity. Similarly, clinical labs worldwide rely on our products to provide high-quality results and optimize workflow efficiency. With products for clinical chemistry, microbiology and hematology labs, our innovative solutions enable the delivery of accurate and timely patient results to help improve health outcomes and help simplify workflows to support an increase in lab productivity. Our newest addition, the Artel portfolio, includes leading analytical instruments, software and services that validate, automate, and calibrate critical liquid handling processes and instrumentation. We are a global leader with products supported by a worldwide network of direct salespeople and distributors, with 24/7 technical support. Our direct presence is growing as we continue to expand the team with a continued focus on being the supplier of choice. Contact us if you are interested in joining a dynamic team! For more information, visit www.aicompanies.com.

CELLINK

CELLINK is proud to be a part of BICO, the world’s leading bioconvergence company. By releasing the first universal bioink in 2016, CELLINK democratized the cost of entry for researchers around the world and played a major role in turning the then up-and-coming field of 3D bioprinting into a thriving $1 billion industry. The company’s best-in-class bioinks, bioprinters, software and services are trusted by the foremost academics in a range of applications, from 3D cell culturing to tissue engineering to drug development, and have been cited in over 700 publications. Furthermore, more than 1,000 laboratories, including ones at the top 20 pharmaceutical companies, are using these award-winning innovations. As part of BICO’s bioconvergence revolution, CELLINK is dedicated to making the on-demand bioprinting of human organs and tissues a future reality and creating the future of health.

Aker BioMarine ASA

Aker BioMarine is a leading human health and nutrition innovator that develops krill-derived products for consumer health and nutrition. We bring our nutrient-rich, all-natural krill ingredient to the pharmaceutical and nutraceutical markets through our leading brands: Superba Krill Oil, Lysoveta, Understory, and Kori Krill. Our innovative approach also extends into our spin-offs FloraMarine (plant-based source of omega-3 from algae), AION (reduce and recycle plastic waste across industries), and Understory (our protein brand). The brand results from our belief that krill is an ancient natural resource and a nutritional opportunity to improve life on our planet.  Aker BioMarine is listed on Oslo Stock Exchange (AKBM).